Barclays PLC Boosts Position in Aemetis, Inc. (NASDAQ:AMTX)

Barclays PLC grew its holdings in Aemetis, Inc. (NASDAQ:AMTX) by 274.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,496 shares of the specialty chemicals company’s stock after acquiring an additional 34,816 shares during the period. Barclays PLC owned about 0.10% of Aemetis worth $109,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in AMTX. FMR LLC boosted its holdings in Aemetis by 68.2% in the third quarter. FMR LLC now owns 22,531 shares of the specialty chemicals company’s stock valued at $52,000 after purchasing an additional 9,137 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Aemetis by 2,837.1% in the second quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock worth $157,000 after buying an additional 50,528 shares during the last quarter. Wellington Management Group LLP acquired a new stake in Aemetis during the third quarter worth about $177,000. Bank of New York Mellon Corp acquired a new stake in Aemetis during the second quarter worth about $306,000. Finally, Susquehanna Fundamental Investments LLC lifted its holdings in Aemetis by 287.4% in the second quarter. Susquehanna Fundamental Investments LLC now owns 126,078 shares of the specialty chemicals company’s stock valued at $379,000 after acquiring an additional 93,536 shares during the period. Institutional investors and hedge funds own 27.02% of the company’s stock.

Aemetis Stock Performance

Aemetis stock opened at $2.27 on Friday. The company’s fifty day moving average price is $3.13 and its 200 day moving average price is $2.94. The stock has a market capitalization of $112.91 million, a P/E ratio of -1.00 and a beta of 1.47. Aemetis, Inc. has a 1 year low of $2.04 and a 1 year high of $7.03.

Aemetis (NASDAQ:AMTX) last announced its earnings results on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.09. The company had revenue of $81.44 million during the quarter, compared to analyst estimates of $77.79 million. During the same quarter last year, the business earned ($0.59) EPS. Sell-side analysts predict that Aemetis, Inc. will post -2.07 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on AMTX. HC Wainwright reaffirmed a “buy” rating and set a $28.00 target price on shares of Aemetis in a report on Monday, December 23rd. StockNews.com raised shares of Aemetis to a “sell” rating in a report on Friday, January 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.95.

About Aemetis

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.